Control system for radiopharmaceuticals

Patent metadata

Field	Value
Publication number	US-12555658-B2
Application number	US-202117496646-A
Country	US
Kind code	B2
Filing date	Oct 7, 2021
Priority date	Mar 15, 2013
Publication date	Feb 17, 2026
Grant date	Feb 17, 2026

Abstract

Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.

First claim

What is claimed is:

1 . A method of managing a process of manufacturing a plurality of batches of a radiopharmaceutical at a facility, the method comprising:
receiving data relating to performance of a process of manufacturing a first batch of the plurality of batches of a radiopharmaceutical; with at least one processor, generating information about the process of manufacturing the first batch of the plurality of batches of a radiopharmaceutical; using the generated information to determine whether a first problem occurred during the process of manufacturing the first batch of the plurality of batches of a radiopharmaceutical and/or whether a second problem is likely to occur during manufacturing of a subsequent batch; based on the determination, analyzing the first problem and/or the second problem to determine whether to proceed to a manufacture of the subsequent batch, the analyzing comprising using at least one processor to:
evaluate a risk associated with proceeding to the manufacture of the subsequent batch; and
generate an indication based on the analyzing, the generating comprising:
generating the indication instructing the process to stop and not proceed to the manufacture of the subsequent batch when the risk is above a threshold; and
generating the indication instructing the process to proceed to the manufacture of the subsequent batch when the risk is below the threshold; and

causing one or more machines of the facility to execute the manufacture of the subsequent batch when the indication instructs the process to proceed.

2 . The method of claim 1 , wherein:
the indication comprises an indication for the process to (a) proceed to the manufacture of the subsequent batch, or (b) stop and not to proceed to the manufacture of the subsequent batch.

3 . The method of claim 1 , wherein:
the determination of whether to proceed to manufacture the subsequent batch is (a) completed within a time period after a manufacture of the first batch is completed, or (b) performed in real time.

4 . The method of claim 1 , further comprising:
determining whether the first problem occurred during the process of manufacturing the first batch by:
comparing a plurality of characteristics of the process of manufacturing the first batch to a predefined set of characteristics of a radiopharmaceutical manufacturing process, optionally wherein comparing the plurality of characteristics of the process of manufacturing the first batch to the predefined set of characteristics comprises automatically comparing at least a portion of the received data relating to performance of the process of manufacturing the first batch to one or more values of the predefined set of characteristics; and
determining whether the first problem occurred during the process of manufacturing the first batch based on the comparison.

5 . The method of claim 4 , further comprising displaying a digital representation of the predefined set of characteristics in the user interface, the digital representation comprising a plurality of user selectable options, wherein comparing the plurality of characteristics of the process of manufacturing the first batch to the predefined set of characteristics comprises:
receiving, via the user interface, one or more user selections corresponding to one or more of the plurality of user selectable options, wherein each of the one or more user selections corresponds to a respective value; and comparing the respective values of the one or more user selections to one or more values of the predefined set of characteristics.

6 . The method of claim 5 , wherein the each of the plurality of user selectable options corresponds to a respective item of a checklist, the checklist indicating an assessment of the process of manufacturing the first batch.

7 . The method of claim 1 , wherein:
determining whether the second problem is likely to occur during the manufacturing of the subsequent batch comprises assessing a risk associated with the second problem; and the method further comprises generating the indication based on the determining whether the second problem is likely to occur during the manufacturing of the subsequent batch.

8 . The method of claim 7 , wherein assessing the risk associated with the second problem comprises determining a probability of failure during manufacturing of the subsequent batch.

9 . The method of claim 7 , further comprising:
if the assessed risk is above the threshold, determining at least one remediation measure to remedy the problem and prevent the second problem.

10 . The method of claim 7 , wherein:
determining whether a second problem is likely to occur during the manufacturing of the subsequent batch comprises assessing a risk associated with the second problem; and the method further comprises determining at least one remediation measure.

11 . The method of claim 10 , further comprising:
determining whether a performance of the at least one remediation measure allows the process to proceed to the manufacture of the subsequent batch, optionally wherein: the performance of the at least one remediation measure allows the process to proceed to the manufacture of the subsequent batch when the at least one remediation measure can be completed within a time period, further optionally wherein: when it is determined that the performance of the at least one remediation measure allows the process to proceed to the manufacture of the subsequent batch, generating the indication instructing the process to proceed to the manufacture of the subsequent batch; and when it is determined that the performance of the at least one remediation measure does not allow the process to proceed to the manufacture of the subsequent batch, generating the indication instructing the process to stop and not to proceed to the manufacture of the subsequent batch.

12 . The method of claim 1 , wherein the indication comprises an indication of an area of concern in the manufacturing process, optionally further comprising:
using a statistical analysis on the received data to determine whether the received data indicates a deviation from an expected or standard set of data; and generating the indication of the area of concern based on the statistical analysis.

13 . The method of claim 1 , wherein the indication comprises a characteristic of the manufacturing process, and the characteristic is a predicted problem with the manufacturing process, wherein:
generating information comprises generating a trend analysis of at least one parameter of the manufacturing process based on the received data; and the predicted problem is:
a systemic problem with an underlying recipe for synthesizing the radiopharmaceutical;
an excursion of at least one manufacturing process parameter of the manufacturing process that may lead to out of specification pharmaceuticals; or
a future infirmity in the manufacturing process.

14 . The method of claim 1 , generating information comprises populating a database with received data by:
validating the data before storing data in the database such that corrupted data is not stored in the database, wherein validating further comprises generating an alert when the data indicates an out of specification critical parameter, or converting the received data into a common format before storing the data in the database.

15 . The method of claim 1 , wherein generating the indication comprises: providing feedback to the facility, wherein the feedback is provided via (a) e-mail or (b) an electronic posting to a collaboration space accessible to a plurali

Assignees

• Lantheus Medical Imaging Inc

Inventors

• Rhodes Derek F
• Siegler Robert W

Classifications

• G05D21/02

  characterised by the use of electric means · CPC title

• G05B15/02

  electric · CPC title

• G16H70/40

  relating to drugs, e.g. their side effects or intended usage · CPC title

• G06Q30/018

  Certifying business or products · CPC title

• G06Q10/06

  Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling · CPC title